
## Meghan Shea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/125497/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Therapeutic Advances in Respiratory Disease, 2016, 10, 113-129.	2.6	125
2	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, 878-883.	1.1	109
3	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 1037-1042.	1.1	83
4	Financial toxicity in gynecologic oncology. Gynecologic Oncology, 2019, 154, 8-12.	1.4	78
5	Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Network Open, 2021, 4, e2037120.	5.9	73
6	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. Journal of the American Society of Cytopathology, 2018, 7, 133-141.	0.5	56
7	Evaluating meaningful levels of financial toxicity in gynecologic cancers. International Journal of Gynecological Cancer, 2021, 31, 801-806.	2.5	42
8	Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. Gynecologic Oncology, 2020, 157, 357-366.	1.4	41
9	Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. Gynecologic Oncology, 2020, 157, 106-114.	1.4	29
10	Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, e81-e82.	1.1	20
11	Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. Journal of Thoracic Oncology, 2017, 12, e175-e177.	1.1	15
12	Oral chemotherapy education sessions at an academic and community cancer center Journal of Clinical Oncology, 2018, 36, 254-254.	1.6	14
13	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e379-e389.	2.6	13
14	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. Cancer Treatment and Research Communications, 2018, 15, 17-20.	1.7	10
15	Electronic monitoring of patient-reported adherence and symptoms on oral chemotherapy at an academic and a community site Journal of Clinical Oncology, 2018, 36, 283-283.	1.6	9
16	Implementing Electronic Patient-Reported Outcomes for Patients With New Oral Chemotherapy Prescriptions at an Academic Site and a Community Site. JCO Clinical Cancer Informatics, 2021, 5, 631-640.	2.1	5
17	Maintenance PARP inhibitor therapy: is maintaining quality of life enough?. Lancet Oncology, The, 2018, 19, e504.	10.7	3
18	Polymyositis as a presentation of advanced carcinoma of Mullerian origin: A case report and discussion. Gynecologic Oncology Reports, 2018, 25, 1-2.	0.6	2

MEGHAN SHEA

#	Article	IF	CITATIONS
19	Management of recurrent cervical cancer with peritoneal carcinomatosis with HIPEC. Gynecologic Oncology Reports, 2022, 39, 100909.	0.6	1
20	A real-world study of patient characteristics and clinical outcomes in <i>EGFR</i> -mutated lung cancer treated with first-line osimertinib Journal of Clinical Oncology, 2022, 40, e21033-e21033.	1.6	1
21	Reply to R.J. Buckanovich et al. Journal of Clinical Oncology, 2019, 37, 2708-2709.	1.6	0
22	A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC) Journal of Clinical Oncology, 2021, 39, TPS5609-TPS5609.	1.6	0
23	Integrating nursing into oral chemotherapy education Journal of Clinical Oncology, 2016, 34, 81-81.	1.6	0
24	Learning from near misses: Addressing nursing chemotherapy verification fatigue Journal of Clinical Oncology, 2017, 35, 70-70.	1.6	0
25	Improving immune-related adverse event management in a thoracic clinic Journal of Clinical Oncology, 2017, 35, 74-74.	1.6	0
26	Optimization of immune-related adverse event management in a thoracic oncology clinic Journal of Clinical Oncology, 2018, 36, 261-261.	1.6	0
27	Experience of financial toxicity among gynecologic oncology patients Journal of Clinical Oncology, 2018, 36, 90-90.	1.6	0
28	PD-1 antibody pembrolizumab administered at non-standard frequency in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2019, 37, e20617-e20617.	1.6	0
29	Patients' perspectives and outcomes on an oral chemotherapy education and electronic monitoring program Journal of Clinical Oncology, 2019, 37, e18007-e18007.	1.6	0
30	Oral chemotherapy education: Hitting the mark?. Journal of Clinical Oncology, 2020, 38, 221-221.	1.6	0